Phenomenome Discoveries Announces the Successful Validation of OvAware™, a simple blood test for the Early Detection of Ovarian Cancer
SASKATOON, May 12, 2016 /PRNewswire/ – Using its proprietary metabolomics technology, Phenomenome Discoveries Inc. had previously discovered that specific metabolic abnormalities were present in the blood of women suffering from ovarian cancer. The company has subsequently developed a simple test (OvAware™) that can be performed on a single drop of blood. The performance of the test has now been verified in two large studies – one in Japan (99 controls and 112 ovarian cancer patients) led by Dr. Fumio Nomura, MD, Chiba, Japan and one in Canada (1041 controls and 325 ovarian cancer patients) led by Dr. Walter Gotlieb, MD, PhD, Montreal, Canada. In both studies, the blood test was able to detect ovarian cancer with 97% accuracy. The results of these studies will be presented by Dr. Dayan Goodenowe, Founder, President and CEO, Phenomenome Discoveries at the Cancer Diagnostics Conference and Expo in Rome, Italy on June 13th, 2016.